Table 7 Summary of non-coding RNA drugs for different diseases in clinical trials
From: Epigenetics-targeted drugs: current paradigms and future challenges
Drug | Target/Mechanism | Condition(s) | Status/outcome(s) | Phase(s) | Other intervention(s)/drug(s) | Study ID/references |
|---|---|---|---|---|---|---|
MRG-106 | MiR-155 inhibitor | CTCL, MF, CLL, DLBCL, and ATCL | Completed (unpublished) | Phase I | Stable background therapy (simultaneously applied in few participants) | NCT02580552 |
MRG-106 | MiR-155 inhibitor | CTCL, MF | Terminated (due to business reasons) | Phase II | Vorinostat (active comparator) | NCT03713320 |
MRG-106 | MiR-155 inhibitor | CTCL, MF | Terminated (due to eligible subjects receiving treatment in a crossover arm of NCT03713320) | Phase II | — | NCT03837457 |
MRG-110 | MiR-92a-3p inhibitor | Healthy volunteers | Completed (unpublished) | Phase I | Placebo-controlled | NCT03603431 |
MRG-110 | MiR-92a-3p inhibitor | Healthy volunteers | Completed (significant inhibition on targeted miRNA in vivo) | Phase I | Placebo-controlled | NCT034947121151 |
RG-012 | MiR-21 inhibitor | AS | Completed (unpublished) | Phase I | — | NCT03373786 |
MRG-201 | MiR-29b mimic | Healthy volunteers | Completed (unpublished) | Phase I | Placebo-controlled | NCT02603224 |
MRG-201 | MiR-29b mimic | Keloid | Completed (exhibits therapeutic effects and manageable adverse events) | Phase II | Placebo-controlled | NCT03601052 |
MRX34 | MiR-34a mimic | Liver cancer, SCLC, lymphoma, melanoma, MM, RCC, NSLCL | Terminated (due to serious immune-related adverse events) | Phase I | — | |
MRX34 | MiR-34a mimic | Melanoma | Withdrawn (due to immune-related serious adverse events in the phase I study) | Phase I/II | Dexamethasone premedication | NCT02862145 |
TargomiRs | MiR-16 mimic | MPM, NSCLC | Completed (exhibits acceptable safety profile and early signs of therapeutic activity) | Phase I | — | NCT023691981153 |
INT-1B3 | MiR-193a-3p mimic | Advanced solid tumors | Terminated (due to the insufficient funding) | Phase I | — | NCT04675996 |
